Allergy Therapeutics PLC (AGY), the specialist pharmaceutical company focused on allergy vaccination, has announced that it has submitted a Marketing Authorisation Application (MAA) for Grass MATA MPL (a new formulation of Pollinex Quattro) in Switzerland.
The MAA has been submitted to the Swiss regulatory authority, Swissmedic, and, on approval, the product will be distributed by Swiss-based Teomed AG, acquired by the company in 2010. The Swiss allergy vaccine market is estimated to be worth between £8-10 million.
The company’s flagship product, Pollinex Quattro, is sold across Europe on a named patient basis and consists of just 4 injections over 3 weeks, offering sufferers a safe and effective therapy with a much more convenient treatment regime than is currently available.
Manuel Llobet, chief executive of Allergy Therapeutics, said: “This is our 12th MAA submission in 2 years and marks another strategic milestone for the company as not only does it represent the first submission of the Grass MATA MPL MAA outside the EU, it also leverages the distribution capabilities of Teomed AG, our Swiss-based distributor, acquired by the company in 2010.”
Allergy Therapeutics plc is a focused on allergy vaccination. It has a growing, profitable business achieving sales of allergy vaccines of £41 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
MATA MPL is a new formulation of Pollinex Quattro with a smaller injection volume; it is a four injection therapeutic vaccine which is being developed for the treatment of allergic conditions which offers same season relief in as little as three weeks after treatment.
Allergy vaccination or immunotherapy is an effective way of modifying or avoiding disease by influencing the immune system. It is essentially a reinforcement of the body's own defence mechanisms and is similar to preventative vaccination against infectious disease; an area of medicine that has met with spectacular success.